Rheumatic Fever AND Rheumatic Heart Disease

The answer first

Rheumatic Fever AND Rheumatic Heart Disease is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Rheumatic Fever AND Rheumatic Heart Disease to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Shetty G, Khadka P, Khatri D, Hada RP, et al. Bridging Knowledge Gaps in Rheumatic Heart Disease Prevention: A Narrative Review of Educational Interventions Across Resource-Limited Settings Health Serv Insights, 2026.PMID 42459928
2. [2]Chen J, Fan Q, Sang J, Kong S, et al. Inflammatory and hormonal crosstalk linking rheumatic fever to chronic valvular heart disease Mol Biol Rep, 2026.PMID 42417893
3. [3]Miller JA, Kim R, Kadiyala M, Marryshow T, et al. A forgotten cause of chest pain in the United States: a case report on acute rheumatic fever J Med Case Rep, 2026.PMID 42337634
4. [4]Rusingiza E, Mlambo V, Schulick N, Ntirushwa D, et al. Development of National Anticoagulation Guidelines for Pregnant Women with Mechanical Heart Valves in Rwanda Cardiovasc J Afr, 2026.PMID 42315154
5. [5]Paratz E, Zhou X, Tavares CAM, Shah P, et al. Atrial Fibrillation Screening in Those with Rheumatic Heart Disease: A Narrative Policy Content Review Glob Heart, 2026.PMID 42221680
6. [6]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
7. [7]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005
8. [8]Osborne AK, Brown RD, Sillence E Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study JMIR Form Res, 2026.PMID 42467962
9. [9]Moujahid M, Erregui H, Faliouni H, Lakhal Z, et al. Myocardial Infarction With Non-obstructive Coronary Arteries (MINOCA) Revealing Coronary Embolism From Left Atrial Appendage Thrombus in Rheumatic Valvular Atrial Fibrillation Cureus, 2026.PMID 42437247
10. [10]Kayamo LK, Teferi YA, Leta AF Pre-operative MELD-Na score as an independent predictor of post-operative mortality after valve surgery in rheumatic valvular heart disease patients Cardiovasc J Afr, 2026.PMID 42397295
11. [11]AlMejbel HA, AlAhmed MA, Alharbi AM, Ali SM, et al. Nonbacterial thrombotic endocarditis in antiphospholipid syndrome, presenting with severe mitral stenosis, heart failure, and stroke: case report Eur Heart J Case Rep, 2026.PMID 42394726
12. [12]Ramireddi CS, Rai MK, Singh A, Agarwal V, et al. Targeting canonical TGFβ/SMAD3 and ERK1/2 signaling in human valve interstitial cells to modulate immune-fibrotic responses in rheumatic heart disease J Physiol Biochem, 2026.PMID 42461450